Notice of Proposed Sale · 144
Definium Therapeutics, Inc.
DFTXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- DEFINIUM THERAPEUTICS, INC.
- Issuer CIK
- 0001813814
- SEC file number
- 001-40360
- Phone
- 212-220-6633
- Person for whose account securities are to be sold
- MATTHEW THOMAS WILEY
- Relationships to issuer
- Officer
- Street
- ONE WORLD TRADE CENTER
- Street (continued)
- SUITE 8500
- City
- NEW YORK
- State / country code
- NY
- Postal code
- 10007
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 3,097 | 113,752.81 | 134,366,950 | 09/25/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/25/2026 | Restricted Stock Vesting Under a Registered Plan | Issuer | 3,097 | N | 09/25/2026 | Services Rendered |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| MATTHEW THOMAS WILEY | Common | 06/25/2026 | 2,867 | 120,786.71 |
Seller — prior-sale row 1, entry 1
- Name
- MATTHEW THOMAS WILEY
- Street
- ONE WORLD TRADE CENTER
- Street (continued)
- SUITE 8500
- City
- NEW YORK
- State / country code
- NY
- Postal code
- 10007
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 09/25/2026
- Signed
- /s/ Matthew T Wiley
Company context
The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.